Core Viewpoint - Skye Bioscience, Inc. is facing legal action from investors following the failure of its clinical trial for nimacimab, which did not meet its primary endpoint for weight loss compared to placebo [4]. Group 1: Legal Action - A lawsuit has been filed against Skye Bioscience, Inc. by an investor alleging violations of securities laws, claiming that the company made false or misleading statements regarding the effectiveness of nimacimab [4]. - Investors who purchased over $100,000 in Skye Bioscience shares between November 4, 2024, and October 3, 2025, have a deadline of January 16, 2026, to take action [2]. Group 2: Clinical Trial Details - Skye Bioscience initiated the "CBeyond" clinical trial in August 2024, a 26-week study aimed at assessing nimacimab for obesity treatment, with a primary endpoint of an 8% difference in mean weight loss compared to placebo [3]. - On October 6, 2025, the company announced that the nimacimab monotherapy did not achieve the primary endpoint of weight loss compared to placebo, and preliminary analysis indicated lower than expected drug exposure [4].

Core Viewpoint - A lawsuit has been filed against SelectQuote, Inc. for alleged violations of securities laws, claiming misleading statements and undisclosed practices related to Medicare beneficiaries [2]. Group 1: Lawsuit Details - The lawsuit was initiated by an investor who purchased shares of SelectQuote, Inc. (NYSE: SLQT) prior to September 2020 [1]. - Allegations include that SelectQuote directed Medicare beneficiaries to plans that compensated the company best, regardless of the quality of the plans [2]. - The company is accused of not providing unbiased comparisons for Medicare Advantage insurance plans and receiving illegal kickbacks [2]. - As a result of these practices, SelectQuote is said to be vulnerable to regulatory and legal sanctions, including potential violations of the False Claims Act [2]. Group 2: Investor Information - Investors who purchased shares of SelectQuote, Inc. are encouraged to contact the Shareholders Foundation for further information and options [1][3].

Core Viewpoint - A lawsuit has been filed against Dow Inc. by an investor, alleging violations of securities laws related to misleading statements about the company's financial health and ability to manage macroeconomic challenges [2]. Summary by Relevant Sections Lawsuit Details - The lawsuit was initiated on August 30, 2025, by an investor in Dow Inc. (NYSE: DOW) [2]. - The plaintiff claims that Dow Inc. overstated its ability to handle macroeconomic and tariff-related challenges, as well as its financial flexibility to support dividends [2]. - Allegations include that the negative impacts of competitive pressures, declining global sales, and product oversupply were understated, leading to materially false and misleading public statements by the company [2]. Investor Information - Investors who purchased shares of Dow Inc. are encouraged to contact the Shareholders Foundation for further information regarding their options [1][3].

Group 1 - A lawsuit is pending against Fortrea Holdings Inc. for alleged violations of securities laws, specifically concerning the company's financial disclosures and projections [1][2] - The lawsuit claims that Fortrea Holdings Inc. overstated revenue contributions from Pre-Spin Projects and inflated EBITDA targets for 2025, leading to misleading public statements about the company's financial health [2] - Investors who purchased shares of Fortrea Holdings Inc. prior to July 2023 are encouraged to contact the Shareholders Foundation for potential options [1][3] Group 2 - The Shareholders Foundation, Inc. provides services related to shareholder issues, including legal monitoring and information on securities class actions [3] - The organization is not a law firm and does not initiate legal actions, but serves as a public service to inform investors [3]

Core Viewpoint - A lawsuit has been filed against Lineage, Inc. for allegedly making false and misleading statements during its July 2024 IPO, particularly regarding its financial health and customer demand [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the registration statement for Lineage's IPO was misleading, failing to disclose a decline in customer demand due to increased cold-storage supply and destocking of excess inventory from the COVID-19 pandemic [2]. - It is alleged that Lineage's customers have shifted to maintaining leaner cold-storage inventories, impacting the company's revenue and occupancy rates negatively [2]. - The plaintiff argues that instead of the expected stable revenue growth and high occupancy rates, Lineage is experiencing stagnant or declining revenue, occupancy rates, and rent prices [2]. Group 2: Investor Information - Investors who purchased shares of Lineage, Inc. are encouraged to contact the Shareholders Foundation for information regarding their options related to the lawsuit [1][3].

Core Points - A lawsuit has been filed against Alto Neuroscience, Inc. (NYSE: ANRO) for alleged violations of securities laws related to its IPO and subsequent statements [3] - Investors who purchased over $100,000 in shares between February 2, 2024, and October 22, 2024, have a deadline of September 19, 2025, to take action [2] - The lawsuit claims that the effectiveness of ALTO-100 in treating Major Depressive Disorder (MDD) was overstated, leading to misleading public statements about the company's financial and business prospects [3] Company Information - Alto Neuroscience, Inc. is facing legal scrutiny due to allegations that its IPO documents contained false or misleading information regarding its product's effectiveness [3] - The Shareholders Foundation, Inc. is facilitating communication for affected investors and provides services related to shareholder issues and securities class actions [4]